ClinicalTrials.gg
Active, not recruitingNCT06848088Updated Nov 10, 2026

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

A Phase 2 interventional study of Fianlimab+cemiplimab in Melanoma, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Other

Updated Nov 10, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing cemiplimab in Melanoma — 6 open to participants now, 9 under way, 1 of them phase 3. cemiplimab · Melanoma.

Enrollment
10th of 11
28 · median 87
Started
2025
with 1 other
Phase 2
8 of 11
4 open now
Registered
8th of 11
by date
Lead sponsor
5 of 11
Regeneron Pharmaceuticals

Among the 11 studies testing cemiplimab in Melanoma, this one is the 10th largest by enrollment, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 8th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 11 studies testing cemiplimab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cemiplimab in Melanoma, or all of them as a file.
02

Study summary

This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782).

The aim of the current study is to see how safe and effective the study drugs are in a long-term follow-up. No study drug will be given during this study. Cancer status will be monitored, in addition to routine care. The study is also collecting information about general health status, and other treatments that may have been received since participation in study R3767-ONC-1613 (NCT03005782).

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Advanced Skin Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

1. Participants with melanoma who enrolled in cohorts 6, 15, or 16 of study R3767-ONC- 1613 (NCT03005782)

Key Exclusion Criteria:

None

Note: Other protocol-defined Inclusion/ Exclusion criteria may apply

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    With Disease Progression at Enrollment

    Drug: Fianlimab+cemiplimab

  • Other
    No Progressive Disease at Enrollment

    Drug: Fianlimab+cemiplimab

Interventions

  • DrugFianlimab+cemiplimab

    Drug pages: Fianlimab · Cemiplimab

    No study drug administered in this observational study.

    Also known as: REGN3767, REGN2810, Libtayo®

06

What researchers measure

Primary outcomes

  1. Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613

    Time frame: Up to 4 years

Secondary outcomes

  1. Progressive-Free Survival (PFS)

    Time frame: Up to 4 years

  2. Objective Response Rate (ORR)

    Time frame: Up to 4 years

  3. Duration of Response (DOR)

    Time frame: Up to 4 years

  4. Disease Control Rate (DCR)

    Time frame: Up to 4 years

  5. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 4 years

  6. Severity of SAEs

    Time frame: Up to 4 years

  7. Incidence of treatment-related AEs

    Time frame: Up to 4 years

  8. Severity of treatment-related AEs

    Time frame: Up to 4 years

  9. Incidence of anti-cancer therapies received since end of treatment with fianlimab and cemiplimab in study R3767-ONC-1613

    Time frame: Up to 4 years

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2030, 65 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 65 months is above that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2029 → Oct 2030 and completion Oct 2029 → Oct 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 26, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Oct 9, 2030was Oct 2029
CompletionEst.
Oct 9, 2030was Oct 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Nov 10, 2026
Primary completion
Oct 10, 2029→Oct 9, 2030
Nov 10, 2026
Study completion
Oct 10, 2029→Oct 9, 2030
Nov 10, 2026
Enrollment
48 (estimated)→28 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Oct 10, 2029→Oct 9, 2030
    Study completion Oct 10, 2029→Oct 9, 2030
    Enrollment 48 (estimated)→28 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06848088
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Apr 14, 2025
Primary completion
Oct 9, 2030 (estimated)
Completion
Oct 9, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fianlimab · Cemiplimab

Start the discussion